|Bid||63.00 x 900|
|Ask||64.04 x 1000|
|Day's Range||62.50 - 65.00|
|52 Week Range||15.55 - 73.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.07|
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.
Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
CRISPR Therapeutics (CRSP), Intellia Therapeutics, Inc. (NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, Ph.D. (collectively, “UC”), co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology, were granted U.S. Patent No. 10,000,772 (“the ‘772 patent”) today by the U.S. Patent and Trademark Office (USPTO).
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / U.S. markets finished mostly lower on Monday, with the Dow logging its 5th straight decline, on fears of growing trade tensions between the U.S. and China. The ...
Shares of companies betting on the gene-editing technology known as CRISPR fell sharply on Monday after two studies in the science journal Nature Medicine questioned whether some implementations of the technique might compromise a cell’s anticancer safeguards. Editas Medicine (EDIT) dropped to $35 from $39, and Intellia Therapeutics (NTLA) slid to $24 from $27. With no products yet tested in humans, it’s hard to say whether the market has been over- or undervaluing CRISPR, a chemical tool that has revolutionized scientific research in the past decade with the ability to alter specific parts of the genetic instructions that run every cell.
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.
Editas Medicine (EDIT) is a pharmaceutical company focused on developing therapies based on CRISPR-CAS9 gene editing technology. On June 11, EDIT stock fell ~7.8% to close at $36.15 over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
Galmed shot up 204% to $21.33 in morning trading, following positive data about its treatment for liver disease nonalcoholic steatohepatitis (NASH). Jefferies' Michael Yee writes that while Galmed's study formally missed statistical significance on both of its regulatory endpoints, "the trial did show significant trends that could hit significance in a larger trial." Given Galmed's size, he notes that Intercept Pharmaceuticals (ICPT) and Gilead Sciences (GILD), both of which have NASH data due out within the next year, could be another way to play the trend, as he anticipates both moving higher on the data. The rest of the sector wasn't doing as well, but was generally higher: The iShares Nasdaq Biotechnology ETF (IBB) is up 0.4% to $110.37, and the SPDR S&P Biotech ETF (XBI) is 0.8% higher to $96.70.
Crispr Therapeutics (CRSP) is a biotechnology company focused on developing gene-based therapies. On June 11, the stock fell ~12.6% to close at $59.57 over concerns that the CRISPR-CAS9 Gene Therapy causes cancer. The news also impacted Intellia Therapeutics (NTLA) and Editas Medicine (EDIT), which we’ll look at later in this series.
NEW YORK, NY / ACCESSWIRE / June 12, 2018 / CRISPR technology stocks saw losses in Monday trading, which included CRISPT Therapeutics, after a STAT report revealed that using CRISPR/Cas9 technology with a cell's genome may cause cancer. Shares of Cardiome Pharma saw gains on the other hand after revealing encouraging news about the FDA responding regarding its regulatory path forward in the US for its BRINAVESS drug. CRISPR Therapeutics AG shares closed down 12.59% on about 8.2 million shares traded on Monday.
Shares of gene-therapy companies sank in active trade Monday, after a STAT report that editing a cell’s genome with CRISPR/Cas9 technology might cause cancer. The STAT report said studies by scientists, which were published in Nature Medicine, found cells that had their genomes altered using the CRISPR/Cas9 method had the potential to seed tumors inside a patient. Switzerland-based CRISPR Therapeutics AG’s stock (CRSP) plunged 12.6% with volume ballooning to 8.3 million shares— almost five-times the full-day average of 1.7 million shares.